These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28158579)

  • 41. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
    Croom KF; Dhillon S
    Drugs; 2011 Nov; 71(16):2213-29. PubMed ID: 22035518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
    Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
    Salvador J; Manso L; de la Haba J; Jaen A; Ciruelos E; de Villena MC; Gil M; Murias A; Galan A; Jara C; Bayo J; Baena JM; Casal J; Mel JR; Blancas I; Sanchez Rvira P
    Clin Transl Oncol; 2015 Feb; 17(2):160-6. PubMed ID: 25119930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
    Masuda N; Inoue K; Nakamura R; Rai Y; Mukai H; Ohno S; Hara F; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Huang X; Iwata H
    Int J Clin Oncol; 2019 Mar; 24(3):262-273. PubMed ID: 30392115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
    Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
    Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
    J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
    Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
    Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
    Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M
    Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
    Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
    Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
    Dent RA; Kim SB; Oliveira M; Barrios C; O'Shaughnessy J; Isakoff SJ; Saji S; Freitas-Junior R; Philco M; Bondarenko I; Lian Q; Bradley D; Hinton H; Wongchenko MJ; Reilly SJ; Turner N
    Clin Cancer Res; 2024 Oct; 30(19):4329-4338. PubMed ID: 39058425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
    Lobo C; Lopes G; Baez O; Castrellon A; Ferrell A; Higgins C; Hurley E; Hurley J; Reis I; Richman S; Seo P; Silva O; Slingerland J; Tukia K; Welsh C; Glück S
    Breast Cancer Res Treat; 2010 Sep; 123(2):427-35. PubMed ID: 20585851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
    Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
    Inoue K; Ninomiya J; Saito T; Kimizuka K; Kurosumi M
    BMC Cancer; 2018 Jun; 18(1):671. PubMed ID: 29925345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
    Dent R; Oliveira M; Isakoff SJ; Im SA; Espié M; Blau S; Tan AR; Saura C; Wongchenko MJ; Xu N; Bradley D; Reilly SJ; Mani A; Kim SB;
    Breast Cancer Res Treat; 2021 Sep; 189(2):377-386. PubMed ID: 34264439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.